Idaho Medicaid spending on GLP-1 drugs

How much did Idaho Medicaid spend on GLP-1 drugs like Ozempic and Mounjaro in 2025?

Pharmacies were reimbursed at least $46.1 million for GLP-1 drugs paid through Idaho Medicaid in 2025, across at least 45,954 prescriptions, according to CMS’s State Drug Utilization Data. That is the total amount reimbursed, federal and state shares together, before the rebates manufacturers pay states. CMS suppressed 42 rows of 156, so these figures are floors.

Pharmacies were reimbursed at least $12.4 million for GLP-1 drugs paid through Idaho Medicaid in 2026 (quarter 1 only, as posted so far), across at least 12,339 prescriptions, according to CMS’s State Drug Utilization Data. That is the total amount reimbursed, federal and state shares together, before the rebates manufacturers pay states. CMS suppressed 11 rows of 40, so these figures are floors.

By year and ingredient

2020at least $1,890,554No data$3,186,845at least $2,372,481$1,766,697$52,835at least $6,961at least $9,276,374
2021at least $9,052,555No data$3,373,412at least $4,127,728at least $1,019,029$83,928at least $23,778at least $17,680,431
2022at least $19,843,023at least $91,589$2,818,516at least $8,630,082at least $521,151at least $43,701Suppressedat least $31,948,060
2023at least $36,090,542at least $1,533,484$2,056,856at least $9,610,499at least $220,960SuppressedSuppressedat least $49,512,341
2024at least $32,810,332at least $6,448,898at least $716,474at least $5,255,383at least $76,132SuppressedSuppressedat least $45,307,219
2025at least $28,639,026at least $13,235,499at least $185,277at least $4,004,170at least $8,850SuppressedNo dataat least $46,072,822
2026 (Q1)$7,563,869at least $3,652,708at least $40,755$1,134,044No dataSuppressedNo dataat least $12,391,377

By product, 2025

Ozempicat least $27,096,506at least 27,6632 of 14
Rybelsus$726,0217280 of 12
Wegovy$816,4996240 of 20
Mounjaroat least $11,468,088at least 10,82312 of 37
Zepboundat least $1,767,411at least 1,6696 of 21
Liraglutide (generic name listing)at least $42,456at least 8114 of 19
Victoza$142,8212300 of 8
Trulicityat least $4,004,170at least 4,1251 of 17
Bydureonat least $8,850at least 112 of 3
ByettaSuppressedSuppressed1 of 1
SoliquaSuppressedSuppressed4 of 4

By quarter, 2025

Q1 2025at least $11,484,199at least 11,48910 of 37
Q2 2025at least $11,365,348at least 11,26610 of 38
Q3 2025at least $11,948,103at least 11,82612 of 42
Q4 2025at least $11,275,172at least 11,37310 of 39

By quarter, 2026 (posted so far)

Q1 2026at least $12,391,377at least 12,33911 of 40

The amounts are CMS’s “Total Amount Reimbursed” field. CMS’s data dictionary for State Drug Utilization Data says of it:

“This total is not reduced or affected by Medicaid rebates paid to the state. This amount represents both the Federal and State Reimbursement and is inclusive of dispensing fees.”

Its prescription count is “The number of prescriptions reimbursed (by the Medicaid Program ONLY) to pharmacists for the (11-digit NDC) drug for the period covered.”

CMS suppresses some rows (its “Suppression Used” field is true and the counts and amounts are left blank). Here a suppressed row is never counted as zero: a figure that includes suppressed rows is shown as “at least” the sum of the rows CMS did publish, and a figure where every row is suppressed is shown as “Suppressed.” The “Rows suppressed” column gives the count. Where many rows are suppressed, the published sum can be well below the full amount, so floors for different states are not directly comparable.

Fee-for-service and managed care rows are added together. Other states: Medicare and Medicaid spending on GLP-1 drugs.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.